United States Medical Device Regulatory Updates for 2026

1. Key takeaways

Three visible developments in United States medical device regulation for 2026 are: the QMSR takes effect on February 2, 2026 (21 CFR 820 incorporates ISO 13485:2016 by reference, and the inspection process switches to CP 7382.850), the eSTAR templates iterate to version 7.1 with 6.2 retired (2026-08-03), and the HDE population threshold is no more than 8,000 people (21st Century Cures Act section 3052, 2016-12-13). Each development carries its own effective date and its own documentation trail, so they cannot be handled by a single announcement or a single internal memo. Companies planning their 2026 compliance calendar should treat these as fixed reference points around which training, submissions, and system work are scheduled. Because all three developments sit inside the same calendar year, they compound: a submission prepared on the new template will be inspected against the new program under the new system requirements.

2. Legal basis

The three developments rest on the following documents and provisions, as verified on the dates indicated, in force as of the verification date noted at the end of this page.

3. Expert insights

Insight one: the three developments fall respectively on the levels of the system, the tool, and the pathway.

The QMSR changes the system requirements and the inspection method; the eSTAR version iteration changes the submission tool; the HDE threshold changes pathway eligibility for rare disease devices. When a company builds its annual compliance plan, these should be mapped respectively to the quality department, the regulatory affairs department, and the product planning department. Assigning all three to one function dilutes ownership, and in our practical estimate each development needs a named owner who tracks its dates through the year. The three levels also interact: the system owner needs the inspection method from the regulatory owner, and the submission owner needs both before the first filing of the year goes out.

Insight two: eSTAR version iteration follows explicit major and minor version rules with retirement dates.

According to the FDA eSTAR Program page, major version updates correspond to significant policy or regulatory changes (for example 1.2 to 2.0), while minor version updates correspond to other revisions (for example 1.2 to 1.3). The retirement date of version 6.2 is 2026-08-03. This requires companies to establish a version monitoring mechanism. A submission prepared on a retired template version creates avoidable rework, and the retirement dates are published far enough in advance to be incorporated into submission schedules rather than discovered on the filing day. The monitoring mechanism need not be elaborate: a check of the eSTAR page at the start of each submission project, with the version number recorded in the project file, keeps the tool current.

Insight three: the incorporation of the human factors content guidance expands the scope of eSTAR materials.

The human factors content guidance was published on 2026-05-29 and took effect on 2026-08-01, and its content has been incorporated into the nIVD and IVD eSTAR templates. A company that still prepares its materials against an older template will omit the human factors engineering sections. The gap is silent: the template simply contains fields the team has never filled before, pending verification against the current template, which is why the template check belongs at the start of every submission project. Training the human factors reviewers on the effective guidance content before the first template build avoids discovering the gap during internal review.

Insight four: the HDE threshold of 8,000 people comes from a statutory amendment, not an internal FDA adjustment.

Section 3052 of the 21st Century Cures Act (2016-12-13) raised the threshold from 4,000 people to no more than 8,000 people, and this is reflected in 21 CFR 814.100(b), as amended by 82 FR 26349, 2017-06-07. Materials citing the old threshold need updating. Because the change came through statute, it is stable rather than subject to administrative revision, and older company documents, templates, and training slides should be searched for the 4,000 figure and corrected. A document search for the old figure is a one-time task, but it should be repeated whenever marketing or clinical teams publish new material that discusses the HDE pathway.

4. Practical recommendations

• Establish an FDA page monitoring calendar, focusing on the eSTAR version page and the QMSR-related pages, with checks recorded each cycle.
• Treat template retirement dates (such as 2026-08-03) as hard constraints in submission scheduling.
• Prepare human factors engineering sections according to the guidance content effective 2026-08-01.
• Prepare population justifications for rare disease devices on the basis of no more than 8,000 people, and no longer use the 4,000 figure.
• Update fee budgets according to the current Federal Register rate notice.

5. Verification checklist

• □ System adjustments have been completed according to the QMSR effective 2026-02-02
• □ Inspection readiness processes have been updated according to CP 7382.850
• □ The current eSTAR version (7.1) and retirement date (2026-08-03) have been confirmed
• □ Human factors engineering sections have been prepared according to the guidance effective 2026-08-01
• □ Population justifications for rare disease devices follow the no more than 8,000 people threshold
• □ Fee budgets have been updated according to the current Federal Register rate notice

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com